SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and CRISPR Therapeutics AG

SG&A Efficiency: Walgreens vs. CRISPR Therapeutics

__timestampCRISPR Therapeutics AGWalgreens Boots Alliance, Inc.
Wednesday, January 1, 2014511400017992000000
Thursday, January 1, 20151340300022400000000
Friday, January 1, 20163105600023910000000
Sunday, January 1, 20173584500023813000000
Monday, January 1, 20184829400024694000000
Tuesday, January 1, 20196348800023557000000
Wednesday, January 1, 20208820800025436000000
Friday, January 1, 202110280200024586000000
Saturday, January 1, 202210246400027295000000
Sunday, January 1, 20237616200034205000000
Monday, January 1, 20247297700028113000000
Loading chart...

Data in motion

SG&A Efficiency: A Tale of Two Companies

In the ever-evolving landscape of corporate finance, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Walgreens Boots Alliance, Inc., a stalwart in the retail pharmacy sector, and CRISPR Therapeutics AG, a pioneer in gene editing, offer a fascinating contrast. From 2014 to 2023, Walgreens consistently reported SG&A expenses exceeding $17 billion annually, peaking at $28 billion in 2024. This reflects its expansive global operations. In contrast, CRISPR Therapeutics, with its focus on innovation, saw a steady rise from $5 million in 2014 to over $100 million in 2021, before a slight dip in 2023. This 20-fold increase underscores its growth trajectory in the biotech arena. The data highlights the distinct operational scales and strategic priorities of these companies, offering insights into their financial stewardship and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025